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Sepsis is currently a leading cause of death in hospital intensive care units. Previous studies suggest that the pathophysiology of
sepsis involves the hyperactivation of complex proinflammatory cascades that include the activation of various immune cells and
the exuberant secretion of proinflammatory cytokines by these cells. Natural killer T-cells (NKTs) are a sublineage of T cells that
share characteristics of conventional T cells and NK cells and bridge innate and adaptive immunity. More recently, NKT cells
have been implicated in microbial immunity, including the onset of sepsis. Moreover, apolipoprotein E (apoE), a component of
triglyceride-rich lipoproteins, has been shown to be protective in endotoxemia and gram-negative infections in addition to its
well-known role in lipid metabolism. Here, we will review the role of NKT cells in sepsis and septic shock, the immunoregulatory
role of apoE in the host immune response to infection, and propose a mechanism for this immunoregulation.
1. Introduction
Natural killer T (NKT) cells are a heterogeneous and
conserved lineage of T cells that have been implicated in
tumor immunity, autoimmune diseases such as diabetes
and multiple sclerosis, as well as the overall regulation of
the immune system [1]. They were originally defined in
mice as a double-negative cell population (CD4-CD8-) that
coexpresses a T cell receptor (TCR) and NK1.1, a natural
killer (NK) cell surface marker [2]. However, subsequent
studies revealed that this earlier definition was not entirely
accurate and was overly simplified. This is partly due to
the lack of NK1.1 in many commonly used mouse strains
except the C57BL/6 strain, as well as the discovery of a
distinct subset of NK1.1- cells that also exhibited key defining
characteristics of NKT cells [2, 3].
2. Classification and Characteristics of
NKT Cells
Currently, it is proposed that NKT cells can be broadly
categorized into two groups: type I or invariant NKT (iNKT)
cells and type II NKT cells [3]. Both groups are activationally
restricted by the MHC class I-like molecule called CD1d
[3]. CD1d is a member of a family of CD1 glycoprotein
molecules expressed on various antigen-presenting cells
(APCs) associated with β2-microglobulin [4]. Unlike MHC
class I and II molecules that present peptide antigens,
CD1d can bind and present glycolipid and lipid antigens
for recognition by NKT cells [4]. Because many pathogenic
microbes possess lipids and glycolipids as structural elements
(e.g., lipopolysaccharide), the discovery of a potential system
for T cell-mediated recognition of these macromolecules
held large implications for host microbial immunity.
A major difference between type I and II NKT cells lays
in the components of their T cell receptors (TCRs) and
their known ligands. iNKT cells express semi-invariant α/β T
cell receptors (TCRs) consisting of an invariant Vα14/Jα18
chain in mice (Vα24/Jα18 in humans) and a restricted
β chain [3]. Despite having well-characterized TCRs, the
endogenous ligands of iNKT cells are still unknown. One
potential lipid proposed to be an in vivo ligand of iNKT cells
is isoglobotrihexosylceramide (iGb3). iGb3, in conjunction
with CD1d, has been implicated in the positive selection
of iNKT cells in the thymus as well as in the peripheral
activation of iNKT cells by dendritic cells (DCs) [5].
However, there is lack of evidence that iGb3 is expressed
in mouse or human thymus, and mice deficient in iGb3
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synthase still experience normal iNKT cell development and
function [5, 6]. This suggests that iGb3 is unlikely to be the
endogenous lipid ligand responsible for thymic iNKT cell
selection and activation.
In the absence of physiological ligands, alpha-galactosyl-
ceramide (α-GalCer), a synthetic glycosphingolipid (GSL)
derived from marine sponges, is the most potent known
agonist of iNKT cells and an indispensable tool in studying
the impact of NKT cell activation on microbial immunity
[7, 8]. In contrast to iNKT cells, type II NKT cells are
nonresponsive to α-GalCer and possess a more diverse
TCR repertoire [3]. Sulfatide, a self-glycolipid derived from
myelin, has been shown to bind to murine CD1d and be
recognized by a subset of type II NKT cells [9, 10]. It has
been suggested that type II NKT cells activated by sulfatide
treatment can mediate anergy in iNKT cells, and thus, have
potential therapeutic applications for inflammatory diseases
in which iNKT cells have been strongly implicated, including
antitumor immunity, autoimmune disease, and asthma [11].
Despite increasing research on type II NKT cells, rel-
atively little is known about them. iNKT cells remain the
prototypical NKT cell type more extensively studied. The
immunoregulatory function most characteristic of NKT cells
is their ability to promptly secrete large amounts of Th1
and Th2 cytokines including IFN-γ and IL-4, respectively,
upon stimulation [12, 13]. Downstream, this culminates in
the activation of cell types of the innate immune system
such as macrophages, NK cells, and dendritic cells as well
as effector T cells of the adaptive immune system. In
addition to cytokine production, NKT cells also possess
cytotoxic effector activity by way of lysis of target cells that
is dependent on perforin and FasL [14, 15]. Although shown
to mediate immunity against a wide range of pathogenic
microbes, including bacteria, fungi, parasites, and viruses,
the mechanism(s) by which NKT cells are activated during
infection is still unclear [16]. Nevertheless, it is this ability
to mount rapid responses to a variety of pathogens and
subsequently activate other cell types that indicates a critical
role for NKT cells in bridging innate and acquired immunity.
3. iNKT Cells Contribute to
the Pathogenesis of Sepsis
Sepsis is a life-threatening condition that continues to be
a chief cause of death in intensive care units [17]. Despite
over two decades of research, the pathogenesis of sepsis
is still incompletely understood, and there are no effective
therapies beyond supportive care and antibiotics. In sepsis,
systemic exposure to pathogenic microbial lipids initiates
a complex and dysregulated immune response. Previous
studies have provided evidence that this immune response
consists of an initial hyperreactive phase and a latent phase.
The initial hyperreactive phase is characterized by the large
release of pro-inflammatory cytokines (i.e., tumor necrosis
factor (TNF), IL-1, and IFN-γ) from activated monocytes,
macrophages, and other immune cells. The latent anti-
inflammatory or immunosuppressed phase increases in
strength in the late stages of sepsis. This latter phase is
Table 1: Summary of proposed role of NKT cells in experimental
models of sepsis.
Experimental
model
Role of NKT Cells Reference
Generalized
Schwartzman
reaction
Deleterious: anti-NK1.1
Ab-treated, β2m−/− and
Jα281−/− mice were protected
[19, 20]
Endotoxemia
(single i.v. LPS
injection)
Deleterious: Jα18−/− mice were
protected
[21]
No role: β2m−/− and Jα18−/−
mice were more susceptible to
LPS-induced shock
[22]
Polymicrobial
sepsis (cecal
ligation and
puncture)
Deleterious:
(a) pretreatment with
anti-CD1d blocking Ab
decreased septic mortality
[23]
(b) β2m−/− mice treated with
anti-asialo GM1 Ab and Jα18−/−
mice had improved survival
[24, 25]
No role: CD1-KO mice exhibited
no significant difference in
survival; mice depleted of NK
cells were protected
[26]
characterized by hypotensive shock, inability to clear the
infection, increased susceptibility to nosocomial infections,
and possible multiple organ failure and death [18]. Because
iNKT cells are potent producers of IFN-γ and other pro-
inflammatory mediators, they were thought to be significant
promoters of the dysregulated septic response. To better
understand how iNKT cells contribute to the pathophysiol-
ogy of sepsis, researchers have investigated the role of these
cells in various experimental models that mimic the clinical
signs and symptoms of sepsis (Table 1).
4. Endotoxic Shock and Gram-Negative
Bacterial Infections
Lipopolysaccharide (LPS), the endotoxin of gram-negative
bacteria, has long been considered a primary structural
component of bacteria that is responsible for initiating the
septic inflammatory response [27]. LPS binds to CD14
expressed on the surface of macrophages and other myeloid
lineage cells, triggering an intracellular signal that is depen-
dent on toll-like receptor (TLR), and ultimately leads these
cells to secrete many pro-inflammatory mediators [28–31].
Administration of nanogram quantities of LPS to patients
was found to reproduce clinicopathological signs of sepsis
including the activation of complement and coagulation
cascades as well as the increased release of pro-inflammatory
cytokines [32]. Intravenous injection of larger doses of
endotoxin can lead to hypotensive shock and multiple organ
dysfunction in a matter of hours [33]. In light of this
relationship between LPS and the development of a host
septic response, LPS has been commonly used to generate
experimental models of sepsis.
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One such model is the generalized Shwartzman reaction,
a lethal shock syndrome in mice that is induced by two
consecutive injections of LPS: a priming followed by a
challenging dose. IFN-γ is considered a key cytokine in
the pathogenesis of the generalized Shwartzman reaction
because IFN-γ can elicit the large production of TNF-α, IL-1,
and other inflammatory mediators [34–36]. Recent studies
have found that because it induces IFN-γ, IL-12 is crucial
for the priming phase. In fact, IL-12 and IFN-γ reportedly
can replace the LPS priming dose in sensitizing mice and
producing significant mortality after further challenge with
LPS [35, 36]. APC-derived IL-12 strongly activates NK1+
T cells to promptly secrete vast amounts of IFN-γ [37].
In addition, LPS activates and increases the cytotoxicity of
NK1.1+ T cells in the liver through IL-12 produced by
Kupffer cells [38]. These findings thus influenced additional
studies on the contribution of NKT cells to the development
of lethal endotoxic shock. In mice depleted of NK1 + αβ T
cells and NK cells by anti-NK1.1 Ab, and in mice deficient
in B2-microglobulin (β2m−/−) and lacking most of their
NK1 + αβ T cells, IFN-γ production was reduced after IL-12
priming, and consequently, the mice were protected against
mortality upon subsequent LPS challenge [19]. Similarly,
a study that examined the systemic Shwartzman reaction
in iNKT cell-deficient (Jα281-deficient) mice found that
when primed with either LPS or IL-12, they had a survival
advantage and concurrently lower serum levels of IFN-γ and
TNF-α than did wild-type C57BL/6 mice [20]. Activation
of iNKT cells alone by injection of the glycolipid α-GalCer
was recently shown to effectively replace the LPS priming
dose in the generalized Shwartzman reaction [39]. Taken
together, these findings indicate a primary role for NKT cells
in initiating an excessive pro-inflammatory response and
promoting lethality in endotoxic shock.
Given that the development of endotoxic shock appears
to be driven by disproportionate Th1 cytokine secretion,
studies have investigated the therapeutic potential of α-
GalCer in influencing the Th1/Th2 cytokine profile released
by iNKT cells. Depending on the length and time of in
vivo exposure to α-GalCer, this glycolipid strongly activates
iNKT cells to secrete variable amounts of Th1 and/or Th2
cytokines. Studies have provided evidence for the ability of
α-GalCer, when administered in repeated doses or coad-
ministered with antigen, to polarize the iNKT cell cytokine
response to a more Th2-like phenotype [40, 41], whereas
others support Th1 polarization by α-GalCer [21, 42, 43].
Although the mechanism underlying these differences is
unclear, the Th2 polarization may be due to a reported
induction of iNKT cell anergy following injection of soluble
α-GalCer [44, 45], characterized by a strong blunting in
IFN-γ production and an inability of iNKT cells to respond
to DC stimulation to produce IFN-γ. Further, bias towards
a Th1 cytokine environment appears to be mediated by
DC maturation and its presentation of α-GalCer [21, 42],
whereas anergy may be induced by non-DC APCs [44, 45].
When used in a mouse model of the systemic Shwartzman
reaction, treatment with α-GalCer prophylactically or shortly
after LPS challenge protected mice against the systemic
Shwartzman reaction [46, 47]. This protection was correlated
with significantly lower serum levels of Th1 cytokines,
including IFN-γ and TNF-α, as well as an increase in
Th2 cytokines such as IL-10 [46, 47]. Protected animals
also exhibited a higher frequency of iNKT cells positive
for intracellular IL-10 and a lower frequency of iNKT
cells positive for intracellular IFN-γ [46, 47]. These results
support a potential therapeutic application for α-GalCer in
modulating and shifting the iNKT cell response to a more
anti-inflammatory phenotype.
In less severe cases of endotoxemia and other microbial
infections, the IFN-γ produced by iNKT cells has been shown
to facilitate pathogen clearance [48]. In an endotoxemia
model induced by a single intravenous injection of LPS,
iNKT cells produced mostly IFN-γ and undetectable levels
of IL-4 after LPS exposure [23]. In that study, iNKT cells
appeared to contribute to endotoxemic mortality, because
Jα18−/− mice deficient in iNKT cells showed greater survival
in association with a strong reduction in IFN-γ levels [23].
In the same study, TNF decreased even more dramatically
early after LPS challenge, which was attributed to insufficient
induction by iNKT cell-derived IFN-γ [23]. Finally, NK cell
activation and production of IFN-γ were also decreased in
Jα18−/− mice, suggesting a role for iNKT cells in amplifying
the immune response by rapidly activating other immune
cell types [23]. All of these findings indicate that iNKT
cells and their early synthesis of IFN-γ are critical to the
complete activation of the pro-inflammatory cascade, which
is important for the proper clearance of infection but may
have deleterious consequences when overly activated.
5. Polymicrobial Sepsis
Although LPS is a fundamental factor in many cases of
sepsis, criticism has arisen over the relevancy of experimental
endotoxemia to clinical sepsis and the accuracy of translating
experimental results to the treatment of septic patients [24].
Cecal ligation and puncture (CLP) is a well-established
animal model of sepsis that closely replicates the features and
clinical course of sepsis including polymicrobial peritonitis
and the development of a hyperinflammatory state that may
lead to a hyporesponsive phase [25]. The CLP procedure
consists of ligation of a percentage of the cecum followed
by perforation of the ligated portion, providing a constant
source of fecal bacteria draining into the peritoneal cavity.
Because CLP meets many of the criteria deemed necessary
for an appropriate sepsis model, it is one of the most widely
used tools to study the mechanisms and pathophysiology of
sepsis and to test the efficacy and safety of pharmaceutical
agents before clinical application.
Administration of anti-CD1d antibody has been demon-
strated to ameliorate systemic lupus erythematosus, airway
hyperreactivity in allergic asthma, and to exhibit potential
antitumor activity [49–51]. Pretreatment with monoclonal
antibody (mAb) blocking CD1d was shown to reduce
CLP-induced mortality compared to IgG-treated controls
and to suppress plasma and splenic levels of the Th2
cytokine IL-10 [52]. Other studies had postulated a role
for NKT cells in the hyperinflammatory phase of sepsis,
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but this study suggested their contribution to the later
immunosuppressed state [52]. However, there have been
new studies demonstrating the agonistic ability of CD1d
mAbs to enhance Th1 responses [50, 53], although these
studies looked at conditions in which there is deficient
protective immunity by iNKT cells and examined the ability
of these antibodies to bypass iNKT activation and directly
stimulate CD1d+ APCs. Another study showed that β2m−/−
mice had prolonged survival relative to wild-type mice after
CLP but did not improve endpoint survival. Additional
depletion of NK cells by anti-asialoGM1 antibody conferred
complete resistance to septic mortality and was associated
with diminished pro-inflammatory cytokine synthesis and
secretion [26]. Similarly, Jα18−/− mice were used to show
that iNKT cell deficiency significantly decreased septic
mortality and ameliorated the systemic pro-inflammatory
response [22]. Despite contradictory findings on the relative
contribution of iNKT cells to a Th1 or Th2 response, these
results consistently implicate a detrimental effect of NKT cell
activation in polymicrobial sepsis.
6. Mechanisms of iNKT Cell Activation
The mechanism(s) by which iNKT cells are activated by
microbial infection remains to be further elucidated. A
“direct” pathway has been reported in which the TCR
of iNKT cells recognizes the GSL cell-wall components
of microbial pathogens, including Sphingomonas bacteria
[54–56]. This early activation of iNKT cells appears to
be important for bacterial clearance, because CD1d−/−
and Jα18−/− mice were impaired in their ability to clear
Sphingomonas [55]. However, this proposedmechanism does
not apply to all models of infection in which iNKT cells have
been implicated. Thus, alternative pathways for activation by
pathogens that do not possess an antigen recognized by the
TCR must exist.
Recent studies have reported an “indirect” pathway with
live Salmonella typhimurium and Salmonella LPS infection
[55, 57, 58]. This consists of a combination of two signals
that culminates in potent IFN-γ secretion by iNKT cells. The
first signal is a weak TCR-mediated response that is generated
from the recognition of CD1d-presented endogenous GSL
antigens. The requirement for self-antigen recognition was
concluded from the observation that CD1d blocking mAb
inhibited iNKT cell activation when cocultured with den-
dritic cells in the presence of S. typhimurium [57]. These
weak responses are amplified by APC-derived IL-12, which
stimulates the IL-12 receptor expressed by iNKT cells after
TLR is activated by microbial products [57, 58]. IL-12 alone
cannot activate iNKT cells when dendritic cells are absent,
which provides further evidence that recognition of self-
ligand is an essential part of this indirect pathway [57, 58].
Yet a third mechanism by which iNKT cells can be
activated in response to bacteria is dependent only on
the APC-derived cytokines IL-12 and IL-18. In iNKT cells
from IL-12−/− mice, production of IFN-γ was impaired in
response to LPS, although not completely abrogated [23].
This impairment was even more significant with iNKT
cells from IL-18−/− mice, suggesting that the iNKT cell
IFN-γ response requires early APC activation and their
production of IL-12 and IL-18 [23]. CD1d-presented antigen
was also shown to be unnecessary for iNKT cell activation
because adding anti-CD1d Ab to cocultures of iNKT cells
with dendritic cells and LPS had little effect on IFN-γ
production, and dendritic cells from CD1d−/− mice were
just as effective in stimulating IFN-γ secretion as those
from wild-type animals [23]. Furthermore, the addition
of either recombinant IL-12 or IL-18 to iNKT cells alone
was sufficient to induce a measurable amount of IFN-
γ production, whereas stimulation with IL-12 and IL-18
combined, even at lower doses, had a synergistic effect and
resulted in considerably enhanced IFN-γ response compared
to incubation with cytokines individually [23]. Because there
were comparable levels of IL-12 and IL-18 following LPS
injection in Jα18−/− and wild-type mice, while there was a
strong reduction in IFN-γ in Jα18−/− mice, it appeared that
iNKT cells were acting downstream of APC-derived IL-12
and IL-18 and were being activated by these cytokines to
produce IFN-γ [23].
All these pathways could potentially be at work in the
pathophysiology of polymicrobial sepsis due to the systemic
release of many microbial stimuli. The mechanism may be
dependent on the nature and strength of the stimulus and
the type of APC that is activated. In addition, these indirect
pathways are postulated to be part of a positive feedback
loop whereby the IFN-γ ultimately produced by iNKT cells
feeds back to further activate APCs [23]. Nonetheless, these
pathways all represent ways in which iNKT cells can quickly
amplify the innate immune response to infection and con-
tribute to the rapid development of the hyperinflammatory
response in sepsis.
7. NKT versus NK Cells as Major Mediators of
Septic Inflammation and Mortality
Some groups have reported that NK cells are more promi-
nent mediators of septic inflammation and mortality than
NKT cells given that NK cells are also known to be potent
producers of IFN-γ. Mice treated with anti-asialoGM1 (NK
cell deficient) or anti-NK1.1 (NK and NKT cell deficient)
were both protected against CLP-induced mortality com-
pared to IgG-treated controls, whereas CD1 knockout mice
(NKT cell deficient) had no significant difference in survival
compared to wild-type controls [59]. This survival benefit
was associated with significantly lower serum concentrations
of IL-6 and MIP-2 [59]. NK cell depletion also decreased
the activation of peritoneal macrophages and other myeloid
lineage cells [59]. Furthermore, NK cell numbers in the
peritoneal cavity increased significantly in CLP versus sham
mice, whereas cell numbers in the spleen and blood
decreased [59]. Similarly, β2-microglobulin-deficient mice
that lack iNKT cells, but not NK cells, as well as Jα18−/− mice
were found to be more susceptible to LPS-induced shock
than wild-type controls [60]. This led to the conclusion
that NK cells rather than NKT cells contribute to septic
inflammation, in part by migrating to the peritoneal cavity,
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where they upregulate the proinflammatory activities of
certain myeloid cell populations [59].
Although NK cells are possibly the more immediate
effector cells in inducing septic shock, NKT cells have been
shown to play a key role in transactivating NK cells at a very
high speed upon stimulation. The glycolipid α-GalCer was
shown to rapidly activate NK cells to produce IFN-γ and
upregulate their expression of the early activation marker
CD69 within hours of exposure, but this effect was abrogated
in CD1-deficient mice lacking NKT cells [61]. The great
rate and magnitude at which NK cells are transactivated by
activated NKT cells led to the postulate that NK cells are
responding to the cytokines that are promptly secreted by
stimulated NKT cells because pretreatment with anti-IFN-γ
Ab partially reduced intracellular levels of IFN-γ and CD69
expression in NK cells [61]. This provides yet more evidence
for the pivotal role of NKT cells as a bridge between innate
and adaptive immunity in initiating an immune cascade that
involves both compartments of the immune system.
8. Lipemia of Sepsis
Early evidence of lipoproteins functioning in innate immu-
nity came from the observation that animals or humans
challenged with infectious agents or LPS exhibit significant
changes in the distribution of their circulating lipoproteins.
This “lipemia of sepsis” was initially described in the late
1950s when patients with cholera were noted to have grossly
lipemic blood and high serum levels of triglyceride (TG)
[62]. The same phenomenon was later observed in patients
experiencing polymicrobial infection [63]. Experimental
studies have shown that the lipemia of sepsis is primarily
due to the accumulation of very low density lipoproteins
(VLDLs) [64]. Although this hyperlipoproteinemia could
simply represent the mobilization of fat stores to fuel the
increased metabolic demands of the host during infections,
the ability of lipoproteins to directly interact with LPS and
other bacterial, viral, and fungal toxins certainly indicates a
function of these particles beyond lipid transport.
Despite a previous focus by others on the interactions
between high density lipoproteins (HDLs) and LPS [65–67],
our laboratory demonstrated that all classes of lipoproteins
can bind and neutralize LPS both in vitro [68, 69], and in
vivo [70], and that infusion with TG-rich lipid emulsion
protected mice against LPS-induced death. Over the past
decade, additional evidence has surfaced supporting a pro-
tective role for lipoproteins against LPS-mediated toxicity. In
the various studies, increased circulating lipoprotein concen-
trations were induced via either (1) the infusion of exoge-
nous lipoproteins [71–73], synthetic emulsion [70, 72], or
recombinant lipoproteins [74–79], (2) genetic manipulation
of the catabolic machinery of lipoproteins [80], or (3) diet
[81]. Despite the differing experimental models, all studies
consistently demonstrated a protective role for increased
systemic concentrations of all classes of lipoproteins against
LPS compared to normolipidemic controls. In addition,
hypolipidemic animals exhibited an increased susceptibility
to LPS toxicity that is reversed when plasma lipid levels are
returned to normal range [71].
9. ApoE Is Protective in Endotoxemia
While the capacity of lipoproteins to bind LPS is accu-
rately predicted by the phospholipid content of the lipid
particles [75, 78], additional protein constituents also play
important roles in the process, including apoE. ApoE, a
component of triglyceride-rich lipoproteins and a ligand of
the low density lipoprotein receptor (LDLR), has a well-
established role in lipid metabolism and cardiovascular
disease. Beyond this, this 299-amino acid, 34.2-kD glyco-
protein synthesized mainly by the liver, but also in many
other organs and tissues including macrophages, as well as
the brain and kidney, is being increasingly recognized as
a pleiotropic molecule that participates in several human
diseases, including Alzheimer’s, dementia, diabetes, breast
cancer, multiple sclerosis, stroke, and kidney disease [82–
84]. More recently, it has emerged as an important regulator
of the host immune response to infection. Consistent with
its ability to facilitate the clearance of TG-rich lipoproteins
by the liver, apoE has been shown to both redirect LPS
from Kupffer cells to hepatocytes, [79] and protect against
endotoxemia in rats [85]. ApoE knockout mice are also more
susceptible to endotoxemia and gram-negative infections
despite their elevated plasma lipid concentrations [86]. In
addition, intravenous apoE protected against endotoxemia in
vivo, further suggesting anti-infective properties [87]. Taken
together, these observations identify apoE as an essential
component of lipoprotein-mediated protection against LPS.
10. ApoE Regulates the Host Septic Immune
Response
Contrary to published evidence documenting the protective
effects of apoE, our laboratory found that injections of apoE
increased CLP-induced septic morbidity and mortality in a
dose-dependent manner [88]. This discrepancy between the
literature and our findings could be attributed to differences
in the experimental models, since the predominant model
is a single injection of one type of endotoxin and a single
dose of apoE, whereas our model uses continuous release
of various types of fecal bacteria and four consecutive
doses of apoE. These seemingly discordant findings led
us to hypothesize that apoE regulates the host response
to severe infection via its effects on NKT cell activation
and the resultant cytokine secretion. In support of our
findings, recent studies have shown that, in human serum,
apoE is the major factor that mediates the presentation of
lipid antigens to CD1-restricted NKT cells and that apoE
specifically enhances T cell responses to a broad range of
microbial lipids through an LDLR-dependent mechanism
[89]. Therefore, we proposed that apoE is fueling iNKT cell
activation and promoting septic mortality by acting as a
molecular chaperone for bacterial antigens, targeting them
for uptake by APCs and the subsequent processing and
presentation of pathogenic lipid fragments to NKT cells in
conjunction with CD1d (Figure 1).
Indeed, we found that the apoE-mediated increase in
septic mortality was also associated with increased splenic
and hepatic iNKT cell frequencies, proliferation and cell
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numbers, and an exacerbated degree of liver injury [88].
Consistent with the pro-inflammatory contribution that
apoE may be making in sepsis, hypomorphic apoE mice
(Apoeh/h) expressing 2−5% of wild-type serum levels of apoE
[90] were found to be less susceptible to septic mortality than
their induced (wt apoE levels) counterparts [unpublished
data]. Higher apoE levels were also associated with increased
Th1 cytokine secretion, as the serum cytokine profile showed
a trend towards greater Th1 cytokine concentrations (TNF,
IL1-β, and IFN-γ) in septic, induced mice compared to
septic, noninduced (low apoE) mice [unpublished data].
Furthermore, it appears that the physiological concentration
of apoE may be regulating a delicate balance point between
sufficient systemic inflammation to clear the invading
pathogen, yet insufficient to harm the host in the process of
eradicating the infection.
11. ApoEPolymorphismsAffect SepticOutcome
The APOE gene codes for three main isoforms, apoE2, E3,
and E4, only differ from each other by a single amino
acid substitution, but possess differential binding affinities
for the LDLR (E4 > E3 ≫ E2) [91]. Recent evidence
has implicated apoE polymorphisms in modulating the
septic inflammatory response and thus, influencing septic
morbidity and outcome. Specifically, in patients, the apoE3
allele has been associated with a lower incidence of sepsis
after elective surgery than the apoE4 allele [92]. In addition,
after LPS exposure, mice expressing human apoE4 produced
more IL-6 and TNF-α than mice expressing human apoE3
[93]. Furthermore, apoE4 mice were shown to be more sus-
ceptible to CLP-induced septic mortality than apoE3 mice,
and this was associated with enhanced pro-inflammatory
cytokine production [94]. That same study also showed
that apoE-mimetic peptides that bind and block the apoE-
binding region of LDLR reduced septic mortality and pro-
inflammatory cytokine levels [94]. Similarly, our laboratory
has demonstrated that treatment with heparin, shown to
bind and inhibit the LDLR-binding region of apoE [95],
promotes survival after CLP-induced sepsis [unpublished
data]. Taken together, these findings provide further support
for our hypothesis that apoE promotes septic mortality and
a Th1 cytokine response by NKT cells via a mechanism
mediated by LDLR. In particular, the apoE3 allele and
mimetic peptides are linked to improved septic outcome
because in both cases, there is decreased binding of apoE to
LDLR and possibly inhibited delivery of bacterial antigens
to APCs for presentation to iNKT cells and subsequent
activation.
12. ApoE May Enhance Presentation of
Endogenous Lipid Antigens
Despite evidence that iNKT cells are activated in response
to LPS in vivo [23], apoE failed to enhance iNKT cell
activation when added to cocultures containing purified LPS
or heat-killed bacteria containing LPS [96]. Instead, apoE
significantly increased iNKT cell activation in response to
LDLr
Early endosome
Late endosome
ApoE
Triglyceride-rich
lipoproteins
Lysosome
Antigen-presenting cell
LPS
↑ Activation and
effector functions
↑ TH1 cytokines
NKT
Receptor recycling
compartment
↓ Apoptosis
CD1d
Figure 1: Proposed model of apoE-mediated lipid antigen presen-
tation and NKT cell activation [89]. Pathogenic microbial lipids
(i.e., lipopolysaccharide, LPS) are delivered to APCs as part of a
triglyceride-rich lipoprotein or bound to apoE. The lipid complex
binds to the LDLR, is internalized, and while trafficked through the
endosomal compartments, is processed and loaded onto CD1d for
recognition by NKT cells.
the endogenous ligand analog iGb3 [96]. These in vitro
findings suggest that apoE-mediated antigen presentation
is more prominent with endogenous ligands than with
LPS, although the classic TLR4 pathway of direct LPS
recognition may play a more substantial role in inducing
an inflammatory response in vivo. Although the primary
insult in CLP appears to be the systemic release of LPS,
or other pathogen-associated molecular patterns (PAMPs),
and induction of fecal peritonitis, the traumatic ligation
and puncture of the cecum could result in the release of
endogenous ligands or danger-associated molecular patterns
(DAMPs) that can contribute significantly to inflammation
as well. The contribution of DAMPs to dendritic cell and
iNKT cell activation is not unprecedented, having been
studied in attempts to develop immunotherapies against
malignancies [97]. This evidence potentially expands apoE’s
role in promoting septic mortality to include mediating the
presentation of not only PAMPs, but DAMPs as well, in a CLP
model of sepsis. In light of failed clinical trials of anticytokine
and anti-LPS treatments, [18, 98] apoE antagonism may
hold more promise in conferring protection against bacterial
sepsis since it can potentially act on two separate classes
of molecules that initiate and perpetuate the host septic
immune response.
13. Conclusions
Despite different experimental models, the studies reviewed
here all constitute growing evidence for the large contri-
bution of NKT cells to the dysregulated and overwhelming
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pro-inflammatory response in polymicrobial sepsis and
endotoxic shock. Although many strong correlations have
been made between septic mortality and NKT cell activation
and cytokine production, researchers are still far from
delineating and demonstrating the exact mechanism by
which NKT cells participate in the septic immune response,
or how their activity is regulated in general. In order to
accomplish this, knowledge of the endogenous ligand(s)
of NKT cells is needed. In spite of progress made by the
identification of iGb3, the self-ligand(s) is still unknown, and
investigators anxiously await the discovery of this missing
piece of the puzzle.
Considering the ability of NKT cells to bridge innate and
adaptive immunity and their extensive immunoregulatory
roles, manipulation of these cells provides a promising
therapeutic strategy for sepsis and inflammation. However,
because NKT cells have numerous effector functions and
closely communicate with other cell types, it will be a
challenge to direct the effect of these interventions to a
single mechanism of action. In promoting the onset of
sepsis, there is contradictory evidence of whether NKT
cells are deleterious due to their pro-inflammatory or
anti-inflammatory contribution. To further tailor therapies
that modulate NKT cell activity, more work is needed to
determine what specific factors trigger NKT cells to assume
a Th1 or Th2-like phenotype during sepsis. Nonetheless, the
work done in animal models so far provides insight on the
contribution of NKT cells to inflammation and injury, and
an important foundation upon which to build more targeted
therapies.
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